Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse
Bourreau E, Ginouves M, Prévot G, Hartley M, Gangneux J, Robert-Gangneux F, Dufour J, Sainte-Marie D, Bertolotti A, Pratlong F, Martin R, Schütz F, Couppié P, Fasel N, Ronet C. Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. The Journal Of Infectious Diseases 2015, 213: 105-111. PMID: 26123564, DOI: 10.1093/infdis/jiv355.Peer-Reviewed Original ResearchConceptsL. guyanensis infectionLeishmania RNA virus 1American tegumentary leishmaniasisSymptomatic relapseTreatment failureTegumentary leishmaniasisFirst-line treatment failureDoses of pentamidineLeishmania guyanensis infectionLine treatment failureFirst-line treatmentChronic cutaneous leishmaniasisVirus 1Second-line drugsExperimental murine leishmaniasisInflammatory markersHyperinflammatory responseExtended therapyMurine leishmaniasisTherapeutic choiceSuch complicationsRNA virus 1Persistent infectionCutaneous leishmaniasisRelapse